Last reviewed · How we verify
NCT04337905: New
Virtual Reality (VR) Diagnostic Tool for Attention Deficits/Hyperactivity Disorder (ADHD)
NA trial testing ADHD-VR diagnosis tool in ADHD in 100 participants. Status unknown.
31 December 2020
Quick facts
| Lead sponsor | Tjhin Wiguna |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | diagnostic |
| Enrollment | 100 |
| Start date | 25 May 2019 |
| Primary completion | 31 December 2020 |
| Estimated completion | 31 July 2021 |
| Sites | 1 location across Indonesia |
Drugs / interventions tested
- ADHD-VR diagnosis tool
Conditions studied
- ADHD — all drugs for ADHD →
- Executive Dysfunction — all drugs for Executive Dysfunction →
Sponsor
Tjhin Wiguna
Who can join
Adults 6 to 17, any sex, with ADHD or Executive Dysfunction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Attention deficit/ hyperactivity disorder (ADHD) is a common neurodevelopmental disorder. The common diagnostic of ADHD is based on psychiatric examination and interview. So far, there is not any other diagnostic tool for ADHD nowadays. Therefore, virtual reality (VR) technology can be used as a stimulus, replacing real stimuli, recreating experiences, which are in the real world would be impossible. Consequently, ADHD-VR diagnostic tool development should be started to justify the ADHD diagnosis in psychiatric out-patient clinical services.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04337905
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for ADHD
Currently open trials in the same condition.
- NCT07314333 — A Trial to Assess How Centanafadine Interacts With Stimulants in the Body · Phase 1 · recruiting
- NCT07262853 — Dual Executive Function Training Package · NA · recruiting
- NCT07291453 — Loving Habits: A Feasibility Study of a Support Program for Building New Parent-child Behavioral Habits · NA · recruiting
- NCT07281092 — Comparative Efficacy of Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) · NA · recruiting
- NCT07219810 — Accelerated iTBS Targeting of Working Memory Versus Inhibitory Control in Adolescent ADHD · NA · recruiting
Other Tjhin Wiguna trials
Trials by the same sponsor.
- NCT04343664 — Mental Health Assessment Among Community Member During the Covid-19 Pandemic in Indonesia · unknown
- NCT04329663 — Effectiveness of the Indonesian Computer-based Game · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04337905 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tjhin Wiguna
- Last refreshed: 8 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04337905.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing